Loading...
•
Sep 30, 2021
Alkermes Q3 2021 Earnings Report
Alkermes reported strong Q3 2021 financial results with revenue growth and advancements in its commercial and development portfolios.
Key Takeaways
Alkermes plc reported third-quarter 2021 financial results, with total revenues of $294.1 million, an 11% increase year-over-year. The company reported a GAAP net loss of $29.0 million, or $0.18 per share, and non-GAAP net income of $23.6 million, or $0.14 per share. They reiterated their financial expectations for 2021.
Total revenues for the quarter were $294.1 million, compared to $265.0 million for the same period in the prior year.
Net sales of proprietary products for the quarter were $157.7 million, compared to $142.7 million for the same period in the prior year.
Net loss according to GAAP was $29.0 million for the quarter, or a basic and diluted GAAP loss per share of $0.18.
Non-GAAP net income was $23.6 million for the quarter, or a non-GAAP diluted earnings per share of $0.14.
Alkermes
Alkermes
Alkermes Revenue by Segment
Revenue by Segment
VIVITROL Revenue
CapyFin.comARISTADA Revenue
CapyFin.com Forward Guidance
Alkermes reiterates its financial expectations for 2021 set forth in its press release dated July 28, 2021. These financial expectations assume improvement in patient access to treatment providers and further normalization of the treatment system in the fourth quarter of 2021.
Challenges Ahead
- If patient access does not improve or the treatment system does not normalize as anticipated, the company’s ability to meet these expectations could be negatively impacted.
- If new COVID-19-related disruptions emerge, the company’s ability to meet these expectations could be negatively impacted.
Revenue & Expenses
Visualization of income flow from segment revenue to net income